Deciphera Pharmaceuticals (DCPH) stock forecast for 2022
Last update: September 19, 2022 (06:40)Sector: Healthcare
The share price of Deciphera Pharmaceuticals, Inc. (DCPH) now
What analysts predict:: $17.2
52-week high/low: $37.99 / $6.51
50/200 Day Moving Average: $15.35 / $11.18
This figure corresponds to the average price over the previous 50/200 days. For Deciphera Pharmaceuticals stocks, the 50-day moving average is the support level today.
For Deciphera Pharmaceuticals stocks, the 200-day moving average is the support level today.
Are you interested in Deciphera Pharmaceuticals stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Deciphera Pharmaceuticals stock price in 2022. How much will one Deciphera Pharmaceuticals share be worth in 2022?
Is it worth taking profit / loss on Deciphera Pharmaceuticals stock now or waiting? What are analysts' forecasts for Deciphera Pharmaceuticals stock?
We forecast Deciphera Pharmaceuticals stock performance using neural networks based on historical data on Deciphera Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Deciphera Pharmaceuticals stock prediction results are shown below and presented as a graph, table and text information.
Deciphera Pharmaceuticals stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Deciphera Pharmaceuticals analysts is $17.2.
Today 200 Day Moving Average is the support level (11.18 $).
50 Day Moving Average is the support level (15.35 $).
Historical and forecast chart of Deciphera Pharmaceuticals stock
The chart below shows the historical price of Deciphera Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Deciphera Pharmaceuticals stock price can be found in the table below.
Deciphera Pharmaceuticals (DCPH) Forecast for 2022
Deciphera Pharmaceuticals information and performance
Deciphera Pharmaceuticals, Inc. is a clinical research biopharmaceutical company.
The company develops drugs designed to improve the lives of cancer patients. Her drug candidates include DCC-2618, DCC-3014 and (Rebastinib) Rebastinib. The platform of kinase switching inhibitors developed by the Company suppresses the process of kinase activation. DCC-2618 is an orally administered inhibitor of kinase switching control for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas including glioblastoma multiforme (GBM), and other solid tumors caused by the pan-KIT or PDGFR gene alpha. DCC-3014 is an orally administered potent and highly selective colony stimulating factor receptor 1 (CSF1R) inhibitor. Rebastinib is a potent and selective oral immunokinase inhibitor of TIE2. Rebastinib binds tightly to the binding region (pocket) of the TIE2 switch, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
Deciphera Pharmaceuticals Address
200 SMITH STREET, WALTHAM, MA, US
Market Capitalization: 1 234 204 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -229 407 008 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.378
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 8.07
Enterprise Value (EV) /Revenue
EV To EBITDA: -3.448
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 66822000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Deciphera Pharmaceuticals price target for 2021 by month
Target values for the price of one Deciphera Pharmaceuticals share for Oct 2022.
Pessimistic target level: 15.90
Optimistic target level: 19.43
Target values for the price of one Deciphera Pharmaceuticals share for Nov 2022.
Pessimistic target level: 14.04
Optimistic target level: 17.81
Target values for the price of one Deciphera Pharmaceuticals share for Dec 2022.
Pessimistic target level: 13.74
Optimistic target level: 17.84
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.